000	00000cam 2200000zi 4500
001	9.965451
003	CaOODSP
005	20260925105820
006	m     o  d f
007	cr cn|||||||||
008	250826s2025    onca    ob   f000 0 eng d
040	|aCaOODSP|beng|erda|cCaOODSP
041	0 |aeng|afre
043	|an-cn---
045	|ay1y2
086	1 |aH82-65/2025-PDF
100	1 |aGaudette, Étienne, |d1953- |eauthor.
245	10|aFactors delaying the public listing of drugs in Canada / |cÉtienne Gaudette, Shirin Rizzardo, Kevin R. Pothier, and Mina Tadrous = Facteurs retardant l'inscription dans les listes de médicaments de régimes publics au Canada / Étienne Gaudette, Shirin Rizzardo, Kevin R. Pothier et Mina Tadrous.
246	11|aFacteurs retardant l'inscription dans les listes de médicaments de régimes publics au Canada
264	1|a[Ottawa] : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2025]
300	|a1 online resource (1 page) : |bcolour illustrations
336	|atext|btxt|2rdacontent
337	|acomputer|bc|2rdamedia
338	|aonline resource|bcr|2rdacarrier
500	|a"NPDUIS, National Prescription Drug Utilization Information System."
504	|aIncludes bibliographical references.
520	|a"The time to public listing for new drugs in Canada has been criticized, citing decentralized public payer structure and institutions leading to a prolonged listing process. We aim to identify and analyze key factors contributing to delays in the time-to-listing"--Objective.
546	|aText in English and French.
650	0|aDrug accessibility|zCanada.
650	0|aDrug approval|zCanada.
710	1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body.
788	|tFactors delaying the public listing of drugs in Canada / |efre|w(CaOODSP)9.966263
856	40|qPDF|s1.54 MB|uhttps://publications.gc.ca/collections/collection_2026/cepmb-pmprb/H82-65-2025.pdf
856	4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/posters/factors-delaying-2025poster.html